Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06282978
Title Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors PETHEMA Foundation
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.